Biopsy Devices Market to Reach USD 2.83 Billion by 2031 Driven by Minimally Invasive Diagnostics and Image-Guided Procedures, Says Mordor Intelligence

Mordor Intelligence estimates the biopsy devices market at USD 2.33 billion in 2026 and projects it will reach USD 2.83 billion by 2031, a 3.97% CAGR. Growth is attributed to demand for early cancer diagnosis, image-guided procedures, minimally invasive sampling, and expanding diagnostic infrastructure; AI-assisted imaging and navigation are cited as opportunities. Adoption may be constrained by equipment costs, training requirements, clinical validation, and uneven healthcare access.

Analysis

The investable signal is modest: a low-single-digit market forecast is not, by itself, an earnings catalyst for Becton, Dickinson and Company (BDX) or Boston Scientific (BSX). The key second-order question is whether image guidance and outpatient migration lift higher-value procedure kits and recurring consumables—or mainly shift procedures between care settings while adding equipment, training, and selling costs. AI/navigation may improve targeting, but value could accrue disproportionately to imaging-platform and software providers rather than biopsy-instrument makers. Tissue sampling also remains relevant alongside molecular and liquid-biopsy testing, though broader noninvasive testing could displace some procedures over time.

Near term (days), expect little durable stock impact: this is a vendor-sponsored market estimate, not company-specific order, pricing, or margin evidence. Over 1–3 months, look for company disclosures on biopsy-related launches, procedure volumes, and growth by relevant product line. Over 6–18 months, outpatient adoption and regional access could broaden demand, but reimbursement, clinical validation, and facility economics are gating factors. Do not infer BDX or BSX exposure from their inclusion in the competitive list; verify product-level revenue and growth. The thesis weakens if company disclosures show no corresponding product-line acceleration, or if procedure adoption stalls. The contrarian point: the market-size narrative may overstate shareholder value capture; a growing procedure pool does not ensure pricing power or attractive incremental margins.

Key Decisions for Investors

• No broad BDX/BSX trade on this release alone; the forecast is too modest and lacks company-level revenue or margin attribution.
• Put BDX and BSX on an earnings-call watchlist: verify biopsy-specific product exposure, organic growth, pricing, and whether outpatient procedure gains are translating into consumables demand before adding exposure.
• Track Hologic as a named competitor, especially for breast-biopsy products, but require evidence of share gains or differentiated economics before making a relative-value position.
• Reassess the theme if company disclosures show sustained biopsy-product growth above the broader device portfolio; falsify it if adoption remains weak or incremental sales fail to support margins.